


# The place of immunology

---

Diana Alecsandru  
Consultant Reproductive Immunology  
IVI RMA Madrid. Spain  
[diana.alecsandru@ivirma.com](mailto:diana.alecsandru@ivirma.com)

# SOCIETY in 2020

◆ Increased maternal age in 1st birth



◆ Increased demand Egg donation (7,561 cycles)




**70%**  
**chromosome  
related**

and the rest?

- **Reproductive Immunology**
- **Microbiota? Endometrium and WOI?**



**How much does the uterus matter?**



**PREECLAMPSIA RISK  
HIGHER IN EGG DONATION**

**Other ART**  
(OR, 2.54; P < .0001)

**Natural Conception**  
(OR, 4.34; P < .0001).

**HTA RISK  
HIGHER IN EGG DONATION**

**Other ART**  
(OR, 3; P < .0001)

**Natural Conception**  
(OR, 7.94; P < .008).


## Increased incidence of obstetric and perinatal complications in pregnancies achieved using donor oocytes and single embryo transfer in young and healthy women. A prospective hospital-based matched cohort study

Kenny A. Rodriguez-Wallberg<sup>a,b</sup>, Ann-Sofie Berger<sup>a</sup>, Antonia Fagerberg<sup>a</sup>, Jan I. Olofsson<sup>c</sup>, Christina Scherman-Pukk<sup>a</sup>, Pelle G. Lindqvist<sup>d,e</sup> and Josefine Nasiell<sup>e,f</sup>

<sup>a</sup>Department of Reproductive Medicine, Division of Gynecology and Reproduction, Karolinska University Hospital, Stockholm, Sweden;

<sup>b</sup>Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; <sup>c</sup>Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; <sup>d</sup>Department of Obstetrics and Gynecology, Södersjukhuset, Stockholm, Sweden; <sup>e</sup>Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; <sup>f</sup>Department of Obstetrics and Gynecology, Karolinska University Hospital, Stockholm, Sweden

- ◆ Gestational hypertensive (AOR 4.25)
- ◆ Pre-eclampsia (AOR 3.99)




✓ **Wrong assumption:**


**“NK cells are bad – let’s get rid of them!”**

✓ **A lot of misunderstood immune concepts in the literature**

**uNK cells**



**pbNK cells**



- IVIG, Intralipid, antiTNFa
- Corticosteroids
- AAS, LMWH...



## Reply: First do no harm: continuing the uterine NK cell debate

ARTICLE *in* HUMAN REPRODUCTION · JANUARY 2016

Impact Factor: 4.57 · DOI: 10.1093/humrep/dev290



Ashley Moffett<sup>1,2,\*</sup> and Norman Shreeve<sup>2,3</sup>

human  
reproduction




LETTER TO THE EDITOR

### Immune testing and treatment: still an open debate


D. Alecsandru<sup>\*</sup> and J.A. García-Velasco 2015




# EVT invasión and remodeling of spiral arteries: **crucial steps** for correct placentation



**Extravillous Trophoblast Cells (EVT)**





**Uterine Natural Killer Cells (uNK, dNK)**



Highly polymorphic  
26,512 HLA I+II alleles


Trophoblast:  
**does not express  
HLA class II**





## Single-cell reconstruction of the early maternal-fetal interface in humans

Roser Vento-Tormo et al. Nature. Nov 2018.



**KIR alleles 1,100**





**5.709 HLA-C alleles  
(December 2019)**




uNK **KIR**

Trophoblast cell  
**HLA-C**





- C1C1
- C1C2
- C2C2




# Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation

Shiqiu Xiong,<sup>1</sup> Andrew M. Sharkey,<sup>1</sup> Philippa R. Kennedy,<sup>1</sup> Lucy Gardner,<sup>1</sup> Lydia E. Farrell,<sup>1</sup> Olympe Chazara,<sup>1</sup> Julien Bauer,<sup>1</sup> Susan E. Hiby,<sup>1</sup> Francesco Colucci,<sup>2</sup> and Ashley Moffett<sup>1</sup>

<sup>1</sup>Department of Pathology and Centre for Trophoblast Research, and

<sup>2</sup>Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, United Kingdom.

Reduced trophoblast invasion and vascular conversion in decidua are thought to be the primary defect of common pregnancy disorders including preeclampsia and fetal growth restriction. Genetic studies suggest these conditions are linked to combinations of polymorphic killer cell Ig-like receptor (*KIR*) genes expressed by maternal decidual NK cells (dNK) and HLA-C genes expressed by fetal trophoblast. Inhibitory KIR2DL1 and activating KIR2DS1 both bind HLA-C2 but confer increased risk or protection from pregnancy disorders, respectively. The mechanisms underlying these genetic associations with opposing outcomes are unknown. We show that KIR2DS1 is highly expressed in dNK, stimulating strong activation of KIR2DS1<sup>+</sup> dNK. We used microarrays to identify additional responses triggered by binding of KIR2DS1 or KIR2DL1 to HLA-C2 and found different responses in dNK coexpressing KIR2DL1 compared with dNK only expressing KIR2DL1. Activation of KIR2DS1<sup>+</sup> dNK results in production of soluble products including GM-CSF, detected by intracellular FACS analysis. These findings provide a molecular mechanism explaining how recognition of HLA class I molecules on fetal trophoblast by an activating KIR on maternal dNK may be beneficial for placentation.






The *Tel-B* region of the *KIR B* haplotype protects against disorders of pregnancy, particularly when the fetus has a *C2* gene

Maternal <i>KIR B</i> regions present <sup>A</sup>	<i>KIR</i> genotype frequencies (%) in all controls and affected cases		Maternal <i>KIR</i> frequencies (%) in pregnancies with fetal <i>C2</i>		Maternal <i>KIR</i> frequencies (%) only in pregnancies with fetal <i>C1</i>	
	Controls (n = 592)	Affected (n = 975)	Controls (n = 235)	Affected (n = 513)	Controls (n = 188)	Affected (n = 338)
None ( <i>KIR AA</i> )	27.5	36.9 <sup>C</sup>	17.0	23.4 <sup>G</sup>	11.8	13.0
<i>Cen-B</i> alone	27.4	30.1	14.2	17.7	12.5	12.1
<i>Tel-B</i> alone	19.3	14.6 <sup>D</sup>	11.1	9.4	8.7	6.4
<i>Cen-B</i> plus <i>Tel-B</i>	25.8	18.5 <sup>E</sup>	13.2	9.8	11.3	9.2
All with <i>Tel-B</i> <sup>B</sup>	45.1	33.0 <sup>F</sup>	24.3	19.2 <sup>H</sup>	20.0	15.6
Trend test	$P < 0.001$		$P = 0.002$		NS	


Maternal *KIR AA* frequency is increased in affected compared with control pregnancies when the fetus has more *C2* genes than the mother or when fetal *C2* is inherited paternally

Parameter	OR <sup>A</sup>	<i>P</i>	<i>n</i> (affected/controls)
<b>Effect of relative dose of maternal and fetal <i>C2</i> genes<sup>B</sup></b>			
Fetus had fewer <i>C2</i> genes than the mother	0.97	1.00	177/85
Fetus had the same number of <i>C2</i> genes	1.43	0.06	364/233
Fetus had more <i>C2</i> genes than the mother	2.09 (1.24–3.51)	0.007	188/105
<b>Effect of origin of fetal <i>C2</i> genes<sup>C</sup></b>			
Paternal origin	2.02 (1.14–3.58)	0.022	135/90
Maternal origin	1.11	0.90	91/61

## Maternal-Fetal Interface




Francesco Colucci. Immunogenetics.2017



Mortality of mother and child (brown curve) occurs at the two extremes of birth weight (blue curve). Adapted from Hiby et al (2014), *J Immunol*, 192, 5069-5073.

**PATERNAL HLA-C2**



Recurrent Miscarriage  
Preeclampsia  
Fetal Growth Restriction  
Low Birth Weight

**MATERNAL KIR AA**

**Combinations of Maternal KIR and Fetal HLA-C Genes Influence the Risk of Preeclampsia and Reproductive Success**

Susan E. Hiby,<sup>1</sup> James J. Walker,<sup>2</sup> Kevin M. O'Shaughnessy,<sup>3</sup> Christopher W.G. Redman,<sup>4</sup> Mary Carrington,<sup>5</sup> John Trowsdale,<sup>1</sup> and Ashley Moffett<sup>1</sup>

J Exp Med 2004

Research article

**Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation**

Shiqiu Xiong,<sup>1</sup> Andrew M. Sharkey,<sup>1</sup> Philippa R. Kennedy,<sup>1</sup> Lucy Gardner,<sup>1</sup> Lydia E. Farrell,<sup>1</sup> Olympe Chazara,<sup>1</sup> Julien Bauer,<sup>1</sup> Susan E. Hiby,<sup>1</sup> Francesco Colucci,<sup>2</sup> and Ashley Moffett<sup>1</sup>


JCI 2013

Human Reproduction Vol.23, No.4 pp. 972-976, 2008  
Advance Access publication on February 8, 2008

doi:10.1093/humrep,

**Association of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage**

S.E. Hiby<sup>1</sup>, L. Regan<sup>2</sup>, W. Lo<sup>2</sup>, L. Farrell<sup>1</sup>, M. Carrington<sup>3</sup> and A. Moffett<sup>1,4</sup>

Research article  Related Commentary, page 3801

JCI 2010

**Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2** N=742

Susan E. Hiby,<sup>1,2</sup> Richard Apps,<sup>1,2,3,4</sup> Andrew M. Sharkey,<sup>1,2</sup> Lydia E. Farrell,<sup>1,2</sup> Lucy Gardner,<sup>1,2</sup> Arend Mulder,<sup>5</sup> Frans H. Claas,<sup>5</sup> James J. Walker,<sup>6,7</sup> Christopher C. Redman,<sup>7,8</sup> Linda Morgan,<sup>7,9</sup> Clare Tower,<sup>10</sup> Lesley Regan,<sup>11</sup> Gudrun E. Moore,<sup>12</sup> Mary Carrington,<sup>3,4</sup> and Ashley Moffett<sup>1,2</sup>

<sup>1</sup>Department of Pathology, University of Cambridge, Cambridge, United Kingdom; <sup>2</sup>Centre for Trophoblast Research, Cambridge, United Kingdom;



This information is current as of May 1, 2014.

**Maternal KIR in Combination with Paternal HLA-C2 Regulate Human Birth Weight**


Susan E. Hiby, Richard Apps, Olympe Chazara, Lydia E. Farrell, Per Magnus, Lill Trogstad, Håkon K. Gjessing, Mary Carrington and Ashley Moffett

N=1316






## What about ART?









Embryo implantation



## Embryo implantation




>64% risk of  
exposure to foreign  
HLA-C2




## Maternal KIR haplotype influences live birth rate after double embryo transfer in IVF cycles in patients with recurrent miscarriages and implantation failure

D. Alecsandru<sup>1,\*</sup>, N. Garrido<sup>2</sup>, J.L. Vicario<sup>3</sup>, A. Barrio<sup>1</sup>, P. Aparicio<sup>1</sup>, A. Requena<sup>1</sup>, and J.A. García-Velasco<sup>1</sup>



291 RM patients  
1.304 cycles


**FIGURE 3**



Pregnancy loss according to HLA-KIR combination. Among KIR A haplotype carriers, the risk of pregnancy loss was significantly higher if the embryo transferred was C2/C2 ( $P < .01$ ). Among C1/C1 embryos, the chance or pregnancy loss was significantly higher if the recipient was a KIR B haplotype carrier ( $P < .01$ ). KIR = uterine natural killer cell immunoglobulin receptor.

Morin. KIR haplotype, HLA ligands, and loss risk. *Fertil Steril* 2016.

KIR N=204



■ AA  
■ AB  
■ BB

Higher %

### KIR AA Spain:

- Basque 16.9%
- Cantabria 31.3%
- Granada 26%




# Observational Study - 2020



Miscarriage  
rate  
(%)



Live birth  
rate  
(%)



26.6

34.2


11.6

47.7

7.7


56.4

Miscarriage and LBR (%) in **DET** by KIR haplotype




\* p < 0.001


N<sub>DET</sub> = 84



## EGG DONOR EMBRYO TRANSFERS



LBR by Embryo HLA-C2 on KIR AA





The more differences in the C2 allele between embryo-mother, the lower the LBR on KIR AA

Chi-square p=0.02; Linear-by-Linear Association p=0.00


NS on KIR AB, BB

N= 790 Euploid Embryo Transfers SET







**What can we do for these couples?**




Retrospective study: January 2017 and December 2018



**GROUP 1**



**GROUP 2**



GROUP 1	LBR (%)
Random HLA-C	5.7
HLA-C1C1	48.9


GROUP 2	LBR (%)
Random HLA-C	6.3
HLA-C2 + G-CSF	14.8



**GROUP 1 vs GROUP 2**

OD 6.82


GROUP 1 vs 2	LBR (%)	PREG (%)	MS (%)
HLA-C1C1	48.9	80	13.3
HLA-C2 + G-CSF	14.8	24.4	17.8





\* P < 0.002  
\* P < 0.001

■ LBR (%)  
■ Pregnancy (%)  
■ MS (%)

## Embryo implantation



- 1 The Maternal Immune System **MATTERS**
- 2 DETs **decrease** the LBR in KIRAA patients  
(30-40% women)
- 3 **HIGHER** embryo HLA-C2 means **LOWER** LBR in  
KIRAA
- 4 This is more evident in **EGG DONATION**



# RCT



# SET

→ **KIR-HLA-C MATCHED** EGG DONOR

→ **RANDOM** HLA-C EGG DONORS

- Medical Staff of IVI RMA CLINICS
- Immunology Unit Nurses IVI RMA Madrid
- Andrology Department IVI RMA Madrid

